SCHEMBL5210877

SCHEMBL5210877

NCc1cccc(C(=O)N(CC(=O)O)c2ccccc2)c1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADRA2C P18825 1/20 0.52
LOXL2 Q9Y4K0 3/20 0.47
KMT2A Q03164 4/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
TSHR P16473 2/20 0.44
GAA P10253 1/20 0.44
MEN1 O00255 3/20 0.43
CFD P00746 2/20 0.43
F2 P00734 1/20 0.43
NPC1 O15118 1/20 0.41
ACHE P22303 1/20 0.41
F11 P03951 1/20 0.40
TPSB2 P20231 1/20 0.40
SUCNR1 Q9BXA5 1/20 0.40
PPARG P37231 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6988918 0.91 ADRA2C (0.52) ADRA2CLOXL2KMT2AL3MBTL1TSHR
SCHEMBL5207728 0.82 NPC1 (0.43) ADRA2CL3MBTL1GAAF2NPC1
SCHEMBL7434072 0.81 F2 (0.37) ADRA2CLOXL2F2CYP1A2CYP2C9
SCHEMBL698882 0.81 ADRA2C (0.64) ADRA2CKMT2AL3MBTL1TSHRGAA
SCHEMBL11503382 0.81 ADRA2C (0.49) ADRA2CKMT2AL3MBTL1TSHRGAA
SCHEMBL7432031 0.81 ADRA2C (0.38) ADRA2CLOXL2KMT2AL3MBTL1CFD
SCHEMBL1625707 0.80 F2 (0.53) ADRA2CLOXL2F2
SCHEMBL5628892 0.80 ADRA2C (0.35) ADRA2CLOXL2KMT2AL3MBTL1TSHR
SCHEMBL4803556 0.80 CYP3A4 (0.52) F2NPC1CYP2D6CYP2C9CYP2C19
Trifluoroacetic Acid SCHEMBL5212770 0.80 KMT2A (0.41) ADRA2CLOXL2KMT2AL3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1240154-B1 SERINE PROTEASE INHIBITORS TULARIK LTD (GB) 2007-02-28 EP disclosed
US-7157585-B2 Serine protease inhibitors TULARIK LIMITED (GB) 2007-01-02 US disclosed
US-20050215587-A1 Serine protease inhibitors LIVELY SARAH E 2005-09-29 US disclosed
US-6916957-B2 Serine protease inhibitors TULARIK LIMITED (GB) 2005-07-12 US disclosed
EP-1343561-A1 SERINE PROTEASE INHIBITORS Tularik Limited (GB) 2003-09-17 EP disclosed
US-20030018059-A1 Serine protease inhibitors PROTHERICS MOLECULAR DESIGN LIMITED (GB) 2003-01-23 US disclosed
EP-1240154-A1 SERINE PROTEASE INHIBITORS Tularik Limited (GB) 2002-09-18 EP disclosed
WO-2002047762-A1 SERINE PROTEASE INHIBITORS TULARIK LIMITED (GB) 2002-06-20 WO disclosed
WO-2001044226-A1 SERINE PROTEASE INHIBITORS TULARIK LIMITED (GB) 2001-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215587-A1 Serine protease inhibitors PRSS1, TPSAB1, CMA1 ADRA2C 2090/4885LOXL2 146/4885KMT2A 2346/4885
US-20030018059-A1 Serine protease inhibitors TPSAB1, PRSS1, SERPINB1 ADRA2C 2451/4885LOXL2 148/4885KMT2A 3553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.